Oxis Turbuhaler (Formoterol Fumarate Dihydrate)

Formoterol fumarate dihydrate, the active ingredient in Oxis Turbuhaler, is a long‑acting β2‑adrenergic agonist (LABA) presented as a dry‑powder inhalation formulation for inhalation use. It provides bronchodilation for maintenance therapy in asthma and chronic obstructive pulmonary disease (COPD) in adults. GNH USA supplies Oxis Turbuhaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Formoterol fumarate dihydrate is a bronchodilator that acts on the airway smooth‑muscle pathway to improve airflow. - Asthma: improves long‑term control of symptoms and reduces the frequency of exacerbations. - Chronic obstructive pulmonary disease (COPD): enhances lung function and decreases rescue‑inhaler use. - Exercise‑induced bronchoconstriction: provides pre‑exercise bronchodilation for patients with reactive airway disease.

Formoterol may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects: - Tremor: mild shaking of the hands or limbs. - Headache: transient head discomfort. - Throat irritation: mild soreness or dryness in the throat. - Cough: occasional dry cough after inhalation. - Palpitations: sensation of rapid or irregular heartbeat. - Nausea: mild stomach upset.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of breathing difficulty. - Cardiac arrhythmia: irregular heart rhythm that may require medical attention. - Hypokalemia: low blood potassium levels detectable on laboratory testing. - Severe allergic reaction: rash, itching, swelling, or difficulty breathing. - Hyperglycaemia: elevated blood glucose, particularly in diabetic patients. - Pulmonary hypertension: increased pressure in lung arteries, observed rarely.

When using Oxis Turbuhaler, patients and healthcare providers should consider several safety measures. - Assess asthma/COPD severity: confirm that maintenance therapy with a LABA is appropriate. - Review cardiovascular history: patients with arrhythmias or ischemic disease need careful monitoring. - Monitor potassium levels: especially in patients on diuretics or with renal impairment. - Avoid abrupt discontinuation: sudden stopping may worsen bronchospasm. - Educate on inhaler technique: proper use maximises drug delivery and reduces local irritation. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Formoterol may interact with several drug classes, altering its safety or efficacy profile.

Major Interactions (Avoid): - Beta‑blockers: can diminish bronchodilator effect and precipitate bronchospasm. - Monoamine oxidase inhibitors (MAOIs): may increase risk of cardiovascular side effects.

Moderate Interactions (Monitor Closely): - Diuretics: can exacerbate hypokalemia when combined with a LABA. - Theophylline: may increase the likelihood of tremor and tachycardia. - Anticholinergics: additive bronchodilation may require dose adjustment of one agent. - Corticosteroids inhaled: while not a direct interaction, combined use is common and requires monitoring for systemic effects. - Certain antidepressants (e.g., SSRIs): may modestly raise heart rate when used together.